Caricamento...
mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?
The proof of principle that a drug targeting mTOR can improve survival has been obtained recently from a large randomised trial using temsirolimus as a first-line therapy in patients with advanced poor prognostic renal cell carcinoma. Consistent data have recently shown the important role of the PI3...
Salvato in:
| Autori principali: | , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Nature Publishing Group
2008
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2570519/ https://ncbi.nlm.nih.gov/pubmed/18797463 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604636 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|